$0.27 EPS Expected for National Research Corporation (NRCIB)

January 13, 2018 - By Vivian Currie

 $0.27 EPS Expected for National Research Corporation (NRCIB)

Analysts expect National Research Corporation (NASDAQ:NRCIB) to report $0.27 EPS on February, 13.They anticipate $0.04 EPS change or 17.39 % from last quarter’s $0.23 EPS. NRCIB’s profit would be $4.72M giving it 51.80 P/E if the $0.27 EPS is correct. After having $0.09 EPS previously, National Research Corporation’s analysts see 200.00 % EPS growth. The stock increased 0.07% or $0.04 during the last trading session, reaching $55.94. About 5,645 shares traded or 37.82% up from the average. National Research Corporation (NASDAQ:NRCIB) has risen 28.51% since January 13, 2017 and is uptrending. It has outperformed by 11.81% the S&P500.

National Research Corporation provides analytics and insights for the patient and employee experience in serving the healthcare providers, payers, and other healthcare organizations in the United States and Canada. The company has market cap of $977.39 million. The Company’s portfolio of subscription solutions offer information and analysis services in a range of elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. It has a 63.71 P/E ratio. The firm offers Market Insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate the needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools.

Another recent and important National Research Corporation (NASDAQ:NRCIB) news was published by Globenewswire.com which published an article titled: “National Research Corporation Adopts Class B Reverse Stock Split to Eliminate …” on September 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.